Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide in BAP1 Mutated Advanced Cutaneous Melanoma
NCT07807878Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Jun 2027
- Primary completion
- Jan 2030
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Drugs
- temozolomide
- Conditions
- cutaneous melanoma (CM)
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in cutaneous melanoma (CM), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoint: Overall Response Rate at 84 days. Planned start Jun 2027; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
patients with advanced cutaneous melanoma with a BAP1 mutation
Patient will be treated with temozolomide at a dose of 200mg/m2 from day 1 to day 5, every 28 days, for up to two years
03
Who it enrols
Adult patients with unresectable stage III or metastatic stage IV cutaneous melanoma harboring a pathogenic BAP1 mutation, who have progressed on prior immunotherapy and targeted therapy (if indicated), with ECOG <= 3 and adequate organ function. Excludes patients with prior chemotherapy for melanoma, non-cutaneous melanoma, or active infections.
04
Endpoints
Primary
Overall Response Rate
Beyond the preview
Go deeper on NCT07807878.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07807878.